Compare Clorox Co (CLX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Recursion Pharmaceuticals Inc — how do they compare? Clorox Co trades at $106.99 (market cap $13.09B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: Clorox Co is far larger — about 7.2× Recursion Pharmaceuticals Inc's market cap, and Clorox Co pays a 4.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CLX | RXRX | |
|---|---|---|
Market Cap | $13.09B | $1.81B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $6.79 |
52-Week Low | $86.12 | $2.84 |
Enterprise Value | $18.47B | $1.33B |
Dividend Yield | 4.62% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
